Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1...
Gilead Sciences, Inc. (NASDAQ: NASDAQ:GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.On CNBC's "Options Action," Tony Zhang said that Gilead...
Gilead has spent over $40 billion in the past five years with little to show for it, yet the high-yielding stock offers a haven to investors in this bear market.
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
ABBV faces a significant loss of revenue beginning in 2023 from Humira biosimilarsFor now, the company is turning in steady earnings growthWall Street consensus outlook is...
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | |||||
| Technical Indicators | |||||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.70 | 4.765 | 4.40 | +0.180 | +3.98% | 929.50K | London | |||
| 80.90 | 81.00 | 80.80 | 0.00 | 0.00% | 0.00 | London | |||
| 3,568.00 | 3,568.00 | 3,420.00 | -6.0 | -0.17% | 369.94K | London | |||
| 99.70 | 101.40 | 99.70 | -2.50 | -2.45% | 546.12K | London | |||
| 1.45 | 1.45 | 1.45 | 0.00 | 0.00% | 1.62M | London | |||
| 172.80 | 178.25 | 165.45 | -0.80 | -0.46% | 4.38M | London | |||
| 15.50 | 17.25 | 15.50 | -1.35 | -8.01% | 311.70K | London | |||
| 21.00 | 21.50 | 20.36 | -0.21 | -0.99% | 2.85M | London | |||
| 126.66 | 126.92 | 125.60 | +0.16 | +0.13% | 103.27M | London | |||
| 1,076.00 | 1,154.00 | 1,046.00 | -74.00 | -6.43% | 149.40K | London | |||
| 108.50 | 108.50 | 108.50 | -2.00 | -1.83% | 1.16M | London | |||
| 23.40 | 25.00 | 23.40 | -1.70 | -6.77% | 11.71M | London | |||
| 1.02 | 1.04 | 0.91 | 0.00 | 0.00% | 1.19M | Aquis Exchange | |||
| 274.00 | 281.50 | 273.00 | -8.00 | -2.84% | 315.84K | London | |||
| 39.00 | 41.00 | 38.10 | -2.90 | -6.92% | 366.86K | London |